CorFlow Therapeutics, a Baar, Switzerland-based company advancing diagnostic and therapeutic solutions for restoring healthy microvascular blood flow, raised €44M in Seris B funding.
The round was co-led by Broadview Ventures and Panakes Partners with participation from 415 Capital, Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital.
David Prim of Broadview Ventures, Barbara Castellano of Panakes Partners, Yoann Bonnamour of Merieux Equity Partners, and Rhiya Pau of Laerdal Million Lives Fund have joined the CorFlow Board of Directors.
The company intends to use the funds to accelerate the MOCA II (MVO with CoFITM System Assessment II) pivotal study intended to gain US market clearance. The trial will run in the US and Europe and aims to validate its CoFl system to diagnose MVO in heart attack patients immediately following stent implantation.
Founded in 2016 by Dr. Rob Schwartz, Dr. Martin Rothman and Jon Hoem, and led by Paul Mead, President and Chief Executive Officer, CorFlow is advancing diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. CorFlow’s CoFl system is being developed to provide timely, accurate and consistent detection of MVO while patients are still in the catheter laboratory (cath lab) immediately following the reopening of the larger epicardial arteries with a stent. The technology has been designed to also enable localized delivery of therapeutics to the microvasculature upon MVO diagnosis. CoFl also integrates into standard workflows utilizing existing guide catheter and wire access.
The company is working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse).
FinSMEs
10/09/2024